Table 2

Adjusted ORs from multilevel logistic regression analysis for likelihood of not receiving surgery, for women with ER-positive EIBC diagnosed in England, modelled using various tumour* and patient factors

Total number of women% of women not receiving surgeryModel 1: tumour factors* + deprivation statusModel 2: tumour factors* +deprivation status+comorbidityModel 3: tumour factors* +deprivation status + frailtyModel 4: tumour factors*+ deprivation status + comorbidity + frailtyModel 5: tumour factors*+ deprivationstatus + ageModel 6: tumour factors*+ deprivation status + comorbidity + frailty + age
c-statistic
(95% CI)
0.710 (0.703 to 0.716)0.777 (0.771 to 0.783)0.796 (0.790 to 0.802)0.797 (0.791 to 0.804)0.841 (0.836 to 0.848)0.858 (0.851 to 0.863)
Invasive grade
 G113 35281.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)
 G240 999101.02 (0.95 to 1.10)1.07 (0.99 to 1.15)1.06 (0.98 to 1.15)1.07 (0.98 to 1.16)0.93 (0.85 to 1.01)0.96 (0.88 to 1.05)
 G313 57470.70 (0.64 to 0.77)0.73 (0.66 to 0.81)0.75 (0.68 to 0.84)0.75 (0.67 to 0.83)0.72 (0.65 to 0.8)0.74 (0.66 to 0.83)
Tumour size (T stage)
 1 to 20 mm (T0–1)41 22561.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)
 21 to 50 mm (T2)23 974132.50 (2.36 to 2.65)2.46 (2.31 to 2.61)2.36 (2.21 to 2.51)2.37 (2.23 to 2.53)1.58 (1.48 to 1.68)1.65 (1.54 to 1.76)
 51+mm (T3)2 726112.45 (2.15–2.80)2.51 (2.18–2.88)2.47 (2.14–2.85)2.48 (2.15–2.87)1.79 (1.54–2.07)1.91 (1.64–2.23)
Nodal status (N stage)
 N049 837101.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)
 N115 59470.53 (0.49 to 0.57)0.56 (0.52 to 0.6)0.57 (0.53 to 0.61)0.57 (0.53 to 0.62)0.66 (0.61 to 0.72)0.68 (0.63 to 0.74)
 N22 49430.22 (0.17 to 0.27)0.22 (0.17 to 0.27)0.22 (0.17 to 0.28)0.22 (0.17 to 0.28)0.25 (0.2 to 0.32)0.26 (0.21 to 0.33)
HER2 status
 Positive6 27181.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)
 Negative56 56491.08 (0.97 to 1.19)1.03 (0.93 to 1.15)1.02 (0.92 to 1.14)1.02 (0.92 to 1.14)0.85 (0.76 to 0.96)0.85 (0.76 to 0.96)
 Borderline5 090121.50 (1.31 to 1.71)1.43 (1.24 to 1.64)1.38 (1.20 to 1.59)1.38 (1.20 to 1.59)1.14 (0.99 to 1.32)1.12 (0.96 to 1.30)
IMD status
 1 (most deprived)10 065111.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)
 212 131100.87 (0.79 to 0.95)0.93 (0.84 to 1.02)0.92 (0.83 to 1.01)0.92 (0.84 to 1.02)0.84 (0.76 to 0.93)0.87 (0.78 to 0.97)
 314 13790.77 (0.7 to 0.84)0.89 (0.81 to 0.98)0.88 (0.8 to 0.98)0.9 (0.81 to 0.99)0.7 (0.63 to 0.77)0.78 (0.7 to 0.86)
 415 99880.67 (0.61 to 0.73)0.81 (0.73 to 0.89)0.81 (0.73 to 0.89)0.82 (0.74 to 0.9)0.6 (0.54 to 0.66)0.69 (0.62 to 0.77)
 5 (least deprived)15 59480.66 (0.6 to 0.73)0.83 (0.75 to 0.92)0.84 (0.76 to 0.93)0.86 (0.77 to 0.95)0.6 (0.54 to 0.67)0.72 (0.65 to 0.8)
Age at diagnosis (years)
 Age67 92591.14 (1.14 to 1.14)1.12 (1.11 to 1.12)
Charlson Comorbidity Index
 058 48861.00 (reference)1.00 (reference)1.00 (reference)
 16 259193.66 (3.40–3.95)1.27 (1.14–1.40)1.33 (1.19–1.48)
 22 057357.95 (7.17–8.81)1.48 (1.29–1.70)1.63 (1.40–1.89)
 3+1 1216224.93 (21.79–28.53)2.66 (2.23–3.17)2.94 (2.42–3.57)
SCARF index
 Fit53 80051.00 (reference)1.00 (reference)1.00 (reference)
 Mild frailty7 501112.28 (2.10 to 2.48)2.04 (1.85 to 2.24)1.26 (1.14 to 1.40)
 Moderate frailty4 498276.42 (5.93 to 6.96)4.93 (4.42 to 5.50)2.28 (2.02 to 2.57)
 Severe frailty2 1266027.00 (24.39 to 29.90)16.00 (13.84 to 18.49)5.37 (4.57 to 6.30)
  • *Tumour factors in the model include grade, tumour size (T stage), nodal metastasis (N-stage) and HER2 status.

  • ER, Oestrogen receptor; HER2, Human epidermal growth factor receptor 2; IMD, Index for multiple deprivation; OR, Odds ratio; SCARF, secondary care administrative records frailty.